MHRA – Page 189 – Pharma.Tips

Particulate Matter Oos after packaging change: packaging integrity and CCIT justification

Investigation into OOS for Particulate Matter Post Packaging Change In the pharmaceutical manufacturing landscape, ensuring the integrity of products is critical, especially for sensitive dosage forms such as ophthalmics. A…

Microbial Limits Failure in vaginal gel production: process controls for moulding, filling, and storage

Assessing Microbial Limits Failure during Vaginal Gel Production: Effective Process Controls In pharmaceutical manufacturing, ensuring product quality and compliance with microbial limits is paramount. A deviation related to microbial limits…

Cleaning Validation Failure during inspection readiness: CAPA with effectiveness checks for auditors

Addressing Cleaning Validation Failures to Ensure Inspection Readiness Cleaning validation failures during inspection readiness present significant challenges for pharmaceutical manufacturers, especially in dosage forms like rectal and vaginal products. Such…

Osmolality Oos during method transfer: how to avoid repeat 483 observations

Managing Osmolality OOS During Method Transfer to Prevent Regulatory Action Osmolality Out of Specification (OOS) results during method transfers present a significant challenge to pharmaceutical manufacturers, particularly in the development…

Ph Drift during inspection readiness: GMP investigation and batch disposition

GMP Investigations into pH Drift During Inspection Readiness and Batch Disposition In the dynamic environment of pharmaceutical manufacturing, particularly in the production of rectal and vaginal dosage forms, maintaining critical…

Cleaning Validation Failure in suppository manufacturing: manufacturing vs lab root cause decision tree

Root Cause Investigation of Cleaning Validation Failures in Suppository Manufacturing In the pharmaceutical industry, ensuring compliance with cleaning validation protocols is critical, particularly in the production of suppositories. Despite the…

Pet Failure in suppository manufacturing: manufacturing vs lab root cause decision tree

Understanding Pet Failures in Suppository Manufacturing: A Decision Tree for Root Cause Investigation The manufacturing of suppositories, characterized by its unique formulation and delivery mechanisms, presents particular challenges that manufacturing…

Pet Failure in eye drop manufacturing: risk assessment for sterility assurance

Understanding Pet Failure in Eye Drop Manufacturing: A Comprehensive Risk Assessment for Sterility Assurance Pet failure during the manufacturing of eye drops can significantly compromise product quality and patient safety,…

Suppository Deformation after temperature excursion: GMP investigation and batch disposition

GMP Investigation of Suppository Deformation After Temperature Excursion: A Practical Guide In pharmaceutical manufacturing, maintaining the integrity of dosage forms is paramount. A common issue that arises is the deformation…

Packaging Leakage Complaint after excipient change: packaging integrity and stability justification

Addressing Packaging Leakage Complaints Following an Excipient Change Packaging integrity is a critical factor in ensuring the stability and efficacy of pharmaceutical products. When a packaging leakage complaint arises, particularly…

E&L Failure at stability pull: risk assessment for sterility assurance

Assessing and Investigating Risks Associated with E&L Failure at Stability Pull The detection of extractables and leachables (E&L) failures during stability pulls represents a significant challenge for pharmaceutical manufacturers, particularly…

Ph Drift at accelerated stability: packaging integrity and stability justification

Investigation into pH Drift during Accelerated Stability Testing: Assessing Packaging Integrity and Stability Justifications In the realm of pharmaceutical manufacturing, deviations during stability testing can pose significant challenges. One such…